July 14 (Reuters) - Medicago:
* MEDICAGO SAYS IT BEGAN PHASE I CLINICAL TRIALS FOR ITS PLANT-DERIVED COVID-19 VACCINE CANDIDATE
* MEDICAGO - ANTICIPATE CONTINUING PRODUCTION OF ADDITIONAL COVID-19 VACCINE CANDIDATE MATERIAL IN PARALLEL TO SAFETY, EFFICACY TRIAL
* MEDICAGO - PLANNING A PHASE 2/3 TRIAL TO BE INITIATED THIS OCTOBER FOR COVID-19 VACCINE CANDIDATE
* MEDICAGO - EXPECTS TO BE ABLE TO MANUFACTURE ABOUT 100 MILLION DOSES OF COVID-19 VACCINE CANDIDATE BY END OF 2021
* MEDICAGO - ANTICIPATES THAT NEW COMMERCIAL FACILITY IN QUEBEC CITY WILL HAVE CAPACITY TO PRODUCE UP TO 1 BILLION DOSES OF COVID-19 VACCINE ANNUALLY